Relapse of pediatric acute lymphoblastic leukemia (ALL) remains the main cause of treatment failure after allogeneic stem cell transplantation (alloSCT). A high level of minimal residual disease (MRD) before alloSCT has been shown to predict these relapses. Patients at risk might benefit from a preemptive alloimmune intervention. In this first prospective, MRD-guided intervention study, 48 patients were stratified according to pre-SCT MRD level. Eighteen children with MRD level X1 Â 10 À4 were eligible for intervention, consisting of early cyclosporine A tapering followed by consecutive, incremental donor lymphocyte infusions (n ¼ 1-4). The intervention was associated with graft versus host disease Xgrade II in only 23% of patients. Event-free survival in the intervention group was 19%. However, in contrast with the usual early recurrence of leukemia, relapses were delayed up to 3 years after SCT. In addition, several relapses presented at unusual extramedullary sites suggesting that the immune intervention may have altered the pattern of leukemia recurrence. In 8 out of 11 evaluable patients, relapse was preceded by MRD recurrence (median 9 weeks, range 0-30). We conclude that in children with high-risk ALL, immunotherapy-based regimens after SCT are feasible and may need to be further intensified to achieve total eradication of residual leukemic cells.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Intensification and optimization of chemotherapy regimens have dramatically improved the cure rate. Nevertheless, for a subgroup of ALL patients with resistant disease, allogeneic stem cell transplantation (allo-SCT) constitutes a necessary, potentially curative treatment modality. [1] [2] [3] [4] Still, relapses after alloSCT, usually within 1 year, remain the most important cause of treatment failure. In these cases of resistant disease, curative options are limited, emphasizing the importance of treatment strategies aiming at the prevention of relapse in these high-risk patients.
Several studies have shown that molecular quantification of the level of minimal residual disease (MRD) before allo-SCT has a strong prognostic value to assess the risk for relapse after transplantation. [5] [6] [7] [8] [9] Thus, a relatively high MRD level just before allo-SCT identifies a subgroup of patients with a very high risk for relapse. These patients may potentially benefit from additional treatment modalities in the context of the allo-SCT procedure.
In addition to hematopoietic rescue, allo-SCT could provide an alloreactive graft versus leukemia effect that may contribute to the therapeutic potential. [10] [11] [12] [13] The occurrence of graft versus host disease (GvHD) and reduction of immunosuppressive medication shortly after SCT has been reported to correlate with protection against relapse of ALL albeit less strongly than for other, especially myeloid type, hematological malignancies. 10, [14] [15] [16] The administration of donor lymphocyte infusion (DLI) at the time of overt relapsing ALL was usually not effective. 17 These observations suggest that alloimmune intervention may only be protective against relapse when the load of residual leukemia is limited. 17 On the basis of these observations, we decided to explore in the subgroup of high-risk ALL patients the protective potential of alloreactivity, deliberately induced early after SCT in a prospective two-center study. ALL patients were stratified according to the level of MRD just before allo-SCT. Patients with a high level of MRD were eligible for an intervention that consisted of early tapering of cyclosporine A (CsA) followed by preemptive infusions of incremental doses of donor lymphocytes.
Patients and methods

Inclusion of patients
Sixty consenting patients with ALL (CR1, 2 and 3) eligible for allo-SCT according to the protocols of the Dutch Childhood Oncology Group (DCOG) were included. 18 Donor hierarchy was in line with i-BFM EBMT guidelines. 19 Patients were transplanted in Leiden University Medical Center (LUMC) and University Medical Center Utrecht (UMCU), between 1 May 2001 and 31 January 2007. The study was approved by the institutional review boards. Nonabsorbable antibiotics were administered orally for nonselective suppression of the gastrointestinal microflora (Center LUMC) until 21 days after SCT or for selective decontamination (Center UMCU). 20 Conditioning was total body irradiation-based in all cases according to the DCOG guidelines. Except for HLA identical sibling transplants, serotherapy, that is, anti-thymocyte globulins (ATG (10 mg/kg; Genzyme, Cambridge, MA, USA or 60 mg/kg; Fresenius Biotech, Bad Homburg, Germany) or Campath-1H (1 mg/kg; Bayer, Mijdrecht, the Netherlands), was included in the conditioning regimen. High-resolution DNA typing for HLA-A, -B, -C, -DR and -DQ alleles was performed. Matched unrelated donors were defined as X9/10 allelic match. GvHD prophylaxis included CsA (2 mg/kg/day i.v. aiming for trough levels of 100-150 mg/l) and a short course of MTX (10 mg/m 2 on day þ 1, þ 3 and þ 6) in T-cell-repleted grafts, and CsA only in T-celldepleted unrelated donor grafts. In case of mismatching, T-cell depletion was performed by immunorosetting. 21 Peripheral blood stem cells from mismatched (related) donors were T-cell-depleted by CD34 purification (CliniMACS; Miltenyi Biotec, Auburn, CA, USA) and administered without CsA. GvHD was graded according to Glucksberg. 22 Umbilical cord blood donors were matched at least five out of six.
Measurement of MRD level before transplant
One to two weeks before conditioning, MRD level was determined by real-time quantitative PCR on duplicate bone marrow aspirates. Molecular targets were clonal rearrangements of immunoglobulin heavy and k light chain and T-cell receptor b, d and g chain genes. Leukemia-specific immunoglobulin/ T-cell receptor rearrangements were detected in the diagnostic or relapse specimens as described. [23] [24] [25] [26] [27] [28] Stability of targets, between diagnosis and relapse, was a prerequisite for applicability. RQ-PCR data were analyzed according to the guidelines of the European Study Group on MRD detection in ALL. 29 If analysis with two or three different PCR targets resulted in different tumor-load estimations, the highest MRD level was used subsequently. 30 In n ¼ 11 patients, MRD level was not determined because of lack of (sensitive) targets (7 out of 11) or material (4 out of 11).
Intervention strategy
In MRD hi patients (the intervention arm of the protocol, Figure 1 ), CsA was tapered to 1 mg/kg/day for 1 week at day 28 or 35, in recipients of a T-cell-repleted or T-cell-depleted graft, respectively, and discontinued 1 week later. Recipients of a non-T-depleted graft received 1 lo and MRD neg patients (the nonintervention arm), were treated conventionally. In patients who received non-T-cell-depleted grafts CsA (2 mg/kg/day i.v. or oral dosage aiming for trough levels: 100-150 mg/l) was continued until day þ 100 after SCT and then reduced by 20% per week. In patients who received T-cell-depleted grafts from a mismatched unrelated donor, CsA was continued until day þ 180 and then reduced by 10% per week. Patients with a haploidentical donor were not eligible for the intervention strategy because these patients received no CsA prophylaxis and the risk of evoking life-threatening GvHD after DLI was considered too high. In case of GvHD grade II (or more), interventions were halted and GvHD was treated with systemic steroids (2 mg/kg/day).
Post-SCT follow-up
Median follow-up was 246 weeks after SCT (range 4-429 weeks). After SCT, patients were sampled regularly to monitor MRD levels and chimerism. Blood was collected at monthly intervals and bone marrow at 3-month intervals. In the patients of the intervention arm, samples of blood and bone marrow were taken before each intervention.
Chimerism
Chimerism in peripheral blood stem cells was determined using the PowerPlex 16 system (Promega, Leiden, the Netherlands). The PCR fragments were separated on an ABI 3130 (Applied Biosystems Inc., Foster City, CA, USA). Data analysis was performed using GeneScan and Genotyper software (Applied Biosystems Inc.). In this flow diagram, the inclusion of patients in the two arms of the protocol is depicted. Forty-eight patients were included for follow-up. Eighteen were included in the intervention arm (MRD hi ) whereas the remaining 30 received no intervention. Thirteen of the patients in the intervention arm received early CsA tapering and six patients received between 1 and 4 DLI. Of the three surviving patients, one had spontaneous GvHD, one developed GvHD immediately after early CsA tapering and one showed no clinical signs of GvHD after 3 DLIs. R, relapse; Excl., excluded; TRM, transplant-related mortality.
Statistical methods
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2 -test for categorical data. For every patient the date of SCT, MRD level pre-SCT, dates of CsA tapering and DLI, date of start GvHD X grade II, date of morphological relapse and of death were collected. Event-free survival (EFS) was defined as time from SCT to the first occurrence of relapse or death in remission; patients were censored if protocol was no longer adhered to: that is, if no DLI was given because of lack of consent or lack of availability (in case of cord blood grafts), if treatment with kinase inhibitors was started, if a second SCT procedure or boost of stem cells was necessary or if a DLI was given off-protocol, or at end of follow-up. For EFS probabilities, Kaplan-Meier survival curves were calculated. For time to relapse and time to GVHD, cumulative incidences were calculated accounting for death as competing risk. 33 The log-rank test was used to compare survival probabilities between groups.
Results
MRD levels and stratification
Sixty ALL patients transplanted in two pediatric transplantation centers were included. In 49 out of 60 (82%) patients, pre-SCT MRD level was reliably determined and used for stratification in the post-SCT intervention. The 11 patients with an unknown MRD level were excluded for follow-up as well as 1 MRD hi patient who had a monozygotic twin as donor. The remaining 48 patients were grouped as follows: MRD hi n ¼ 18 (38%), MRD lo n ¼ 15 (31%), and MRD neg n ¼ 15 (31%) ( Table 1) . It should be noted that of the CR1 patients, only 4 out of 21 (19%) were MRD hi , whereas in CR2/3 patients 14 out of 27 (52%) were MRD hi (P ¼ 0.02). T-cell numbers at day 150 (cells per ml; average (standard deviation); intervention group, n ¼ 6; nonintervention group, n ¼ 14). g TRM is defined as death in remission within 6 months after SCT.
h Extramedullary relapses/total number of relapses in that group. Intervention, paravertebral, testis, parotid gland, kidney; nonintervention, testis (n ¼ 2), skull. i Event is defined as relapse or death. Cumulative proportion of surviving patients at 5 years.
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Clinical outcome in the intervention arm
Eighteen patients (MRD hi ) were included in the intervention arm of the protocol (Figure 1 ). Two patients died within 2 weeks after SCT because of causes associated with transplant-related mortality, and three patients developed GvHD grade II before intended tapering of CsA (Figure 1 ). They were treated successfully with systemic steroids and two relapsed at 82 and 99 weeks, respectively (Figure 2 ). In the remaining 13 patients, CsA was tapered 4-5 weeks after SCT. Three of these developed GvHD grade II and thus reached the end point of intervention; two patients relapsed at 22 and 73 weeks after SCT.
Of the remaining 10 patients, 2 relapsed after tapering of CsA and before the first DLI (Figure 2, UPN51 and 34) . Two other patients who qualified for DLI were censored (lack of patient consent and lack of donor cell availability). The remaining six patients received 1-4 DLI as continuation of the intervention. One of those patients relapsed after the first and other after the second DLI. The other four patients received 3-4 DLI without any signs of GvHD. Three of those relapsed and one is in continuous remission (Figures 1 and 2 ). In the intervention group, EFS and cumulative incidence of relapse (CIR) at 5 years after SCT were 19% (s.e. 10%) and 69% (s.e. 11%), respectively (Figures 3a and b) .
The EFS of the MRD hi patients did not differ from that of MRD hi patients reported by us and others in previous retrospective studies. 6, 8, 9 However, although MRD hi patients in the latter studies relapsed almost exclusively within the first year after SCT, relapses in the MRD hi patients in this prospective study occurred over an extended period of 3 years after SCT. Out of 11 relapses, 5 (45%) occurred more than 1 year after SCT. Relapses in the MRD hi patients were also delayed when compared with the nonintervention patients (MRD lo and MRD neg ) in this study; only 2 out of 11 (18%) relapses in the latter group occurred (immediately) after the first year (P ¼ 0.17, Figure 3a) .
In addition to the delayed timing of some of the relapses in the intervention arm, it was noted that there were several unusual extramedullary presentations of relapse, although this observation was not statistically significant (Table 1 ). In the intervention arm, relapses presented in parotid gland, kidney and paravertebral area. Together, the characteristics of the relapses are in line with the assumption that the immune intervention may have altered the features of leukemia recurrence.
Clinical outcome in the nonintervention arm
EFS and CIR at 5 years after SCT in the MRD neg group were 65% (s.e. 13%) and 29% (s.e. 12%), respectively, which is similar to the results reported in previous retrospective studies (Figure 3) . 6, 8, 9 EFS and CIR at 5 years after SCT in the MRD lo group were 31% (s.e. 13%) and 54% (s.e. 14%). As expected, the EFS of the MRD lo group is lower than that of the MRD neg group, although this did not reach statistical significance (P ¼ 0.07; Figure 3a ).
Occurrence of acute GvHD
To evaluate the risk of inducing acute GvHD X grade II by early CsA tapering and DLI administration, the occurrence of acute GvHD was compared between patients included in the intervention arm and those who were not. The frequency of acute GvHD X grade II in patients in the intervention arm was slightly increased compared to patients of the nonintervention arm ( Figure 4 , cumulative incidence of acute GvHD X grade II at 5 years 33 versus 17%, respectively, P ¼ 0.15). Interestingly, these additional events of acute GvHD occurred between 5 and 9 weeks after SCT, after tapering of CsA. In all cases, GvHD was successfully treated with systemic steroids. In six patients, DLI did not lead to induction of GVHD. Within the MRD hi group of patients, six patients developed GvHD grade II and four of those relapsed (67%). Seven of eight evaluable patients who did not develop GvHD grade II relapsed (88%). This difference is not statistically significant (P ¼ 0.35). In patients of the nonintervention arm, there was no significant difference in relapses between patients with or without GvHD, although the number of patients with GvHD X grade II (n ¼ 5) was too low to obtain reliable results. Therefore, there were no indications that GvHD protected patients from relapse.
MRD monitoring after transplantation predicts relapse
To study whether monitoring of MRD and chimerism after SCT may be instrumental to predict relapse, we analyzed 3-monthly bone marrow and monthly blood samples during the first year after SCT. In the nonrelapsing patients that were investigated, no MRD levels X1 Â 10 À4 were detected, either in bone marrow or in blood, at any time point during the first year after SCT (n ¼ 8; data not shown). Sixteen patients who relapsed and of whom sufficient post-SCT MRD and chimerism data on blood and bone marrow were available during the first year after SCT were evaluated ( Figure 5 ). In 14 of those 16 patients, the molecular targets were stable and still present in the relapse material. In one patient with a testicular relapse the target was lost and in the other one relapse material was not analyzed. In 2 out of 16 patients, the leukemia relapsed very rapidly within 12 weeks although post-SCT MRD levels in blood and bone marrow became negative (that is, o1 Â 10 À4 ) immediately after SCT. In 8 out of the 14 remaining patients, a bone marrow and/or a blood sample with a high MRD level (X1 Â 10 À4 ) preceded the clinical relapse by 9 weeks (median, range 0-30) and 8 weeks (median, range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , respectively. The slightly earlier detection in bone marrow occurred despite more frequent sampling of blood than of bone marrow. In one patient the first high MRD detection was in the relapse material and in the remaining five patients, the relapse occurred after the first year of frequent sampling had passed. In all patients MRD levels became negative after SCT, except for patient UPN35 in whom these were still positive immediately after the SCT procedure but became negative afterward.
The predictive value of (changes in) chimerism was investigated in the same samples (data not shown). The two patients who suffered very early relapses (within 3 months after SCT) never fully engrafted with donor hematopoiesis. In five out of nine informative patients, a slight increase in recipient chimerism was noted 1-2 weeks before relapse. Together, these findings show that in a subgroup of patients, frequent monitoring of MRD levels (rather than chimerism) after SCT may identify patients who are progressing to overt relapse.
Discussion
In this first prospective, MRD-guided intervention study in pediatric patients transplanted for ALL, we have explored the feasibility to perform post-SCT alloimmune intervention consisting of early CsA tapering and DLI. As we were concerned that this strategy might result in the undesired induction of serious GvHD, we considered only patients at the highest risk for relapse (that is, MRD level X1 Â 10 À4 ) eligible for the intervention. In our cohort, 18 out of 48 patients fulfilled this criterion.
Interestingly, acute GvHD X grade II occurred only in 23% of the patients after tapering of CsA; all of whom were successfully treated with steroids. DLIs were well tolerated and did not lead to GvHD in any of the cases. This may in part have been related to the numbers of T lymphocytes infused or the time interval between conditioning and DLI. 16 The interventions did not impact on EFS in the MRD hi group as compared to EFS in similar MRD hi patients in previous retrospective studies in which interventions were not included. [6] [7] [8] 34 However, compared to these historical MRD hi patients without intervention, as well as to the MRD lo/neg group in this study, it was observed that an unexpected high proportion of relapses in the MRD hi intervention group presented later than 1 year after SCT. In addition, several of the relapses presented at unusual extramedullary sites, a phenomenon described before in conjunction with DLI. [35] [36] [37] [38] [39] Together, these observations are compatible with the notion that immune intervention may have influenced the timing and presentation of leukemia recurrence. Strong indications for the presence of immunological pressure on leukemic AML cells by the emergence of HLA loss variants have been recently reported. 40 The CIR in the MRD lo and MRD neg groups was lower than recently reported in a similar study using similar technology and cutoff values, namely 1 Â 10
À4
. 34 One difference with the published study is that we included not only CR2/3 patients but also CR1 patients. However, given the better outcome in CR1 patients this difference is unlikely to explain the higher relapse rate in our study (data not shown). In addition, we did not find any correlation between MRD-related outcome and use of serotherapy, donor type and graft manipulation, indicating that these variables probably do not explain the discrepancy between the two studies. Possibly differences in pretransplant Figure 3 Event-free survival (a) and cumulative incidence of relapse (b) according to pre-SCT MRD level. Forty-eight patients with known pre-SCT MRD levels were included for follow-up of relapse-free survival (a) and cumulative incidence of relapse (b). Censoring of patients at defined moments was as described in Patients and Methods section. [41] [42] [43] [44] It has been argued that ALL cells are intrinsically resistant to (alloreactive) T cells although several reports have described that activated T cells do recognize and lyse unmanipulated ALL cells. [45] [46] [47] [48] [49] An alternative explanation for the lack of a clinical effect may be found in the rapid growth characteristics of ALL cells.
To further improve and optimize treatment of high-risk pediatric ALL patients, several strategies may be combined. Because of the good prognostic value of a low pre-SCT MRD level, an intensified, MRD-guided, first-line ALL protocol aimed to achieve MRD negativity before transplantation, even in cases of relatively resistant disease, is warranted and currently explored in clinical trials. After transplantation, further preemptive interventions, for example, DLI may be scheduled. These interventions could be based on frequent, for example, (bi)monthly, post-SCT MRD quantification, and possibly chimerism too, as predictive biological markers of relapse. Our study shows that CsA tapering and DLI can be safely performed in the post-SCT setting. This strategy can now be further optimized in terms of dosage, timing and duration to obtain maximal antileukemic effect. In parallel with the usual prolonged maintenance therapy (up to 2 years) for newly diagnosed and relapsed ALL, it may likewise be necessary to provide continuing immunotherapeutic interventions for a prolonged period of time to eradicate residual leukemic cells. 50, 51 These interventions may be combined with adjuvant therapy and/or supportive chemotherapy to prevent relapses in immuneprivileged sites. 52 
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